Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial

@article{Keech2007EffectOF,
  title={Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial},
  author={A. Keech and Paul Mitchell and Paula H. Summanen and Justin O'day and Tme Davis and Mireille Moffitt and Marja-Riitta Taskinen and R John Simes and Dana Tse and Elizabeth A. Williamson and Alistair Merrifield and LT Laatikainen and M. D'emden and DC Crimet and RL O’Connell and P. G. Colman},
  journal={The Lancet},
  year={2007},
  volume={370},
  pages={1687-1697}
}

The use of fenofibrate in the management of patients with diabetic retinopathy: an evidence-based review.

TLDR
There is firm evidence that fenofibrate slows the progression of diabetic Retinopathy and the need for more invasive treatment modalities in patients with type 2 diabetes, especially those with pre-existing retinopathy.

Medical treatment for diabetic retinopathy: do the FIELD microvascular study results support a role for lipid lowering?

TLDR
Investigation of fibrates in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study has demonstrated a significant 30% relative reduction in the need for first retinal laser therapy in type 2 diabetes patients treated with a fibrate (fen ofibrate).

FIELD Study Revealed Fenofibrate Reduced Need for Laser Treatment for Diabetic Retinopathy

TLDR
The effects of fenofibrate administration on ophthalmic microvascular complications are detailed and some of the underlying pathologies being addressed among patients undergoing laser treatment are clarified.

Pharmacotherapy for diabetic retinopathy

TLDR
Using alone, intravitreal triamcinolone acetonide (IVTA) seems to have some short-term efficacy against DME, but longer-term outcomes using IVTA monotherapy showed a lesser benefit than focal/grid laser treatment in a prospective RCT done by the Diabetic Retinopathy Clinical Research Network.

Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?

TLDR
Results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study show beneficial effects of fen ofibrate in reducing the requirement for laser therapy, and particularly in preventing disease progression in patients with pre-existing diabetic retinopathy.

Association of Fenofibrate and Diabetic Retinopathy in Type 2 Diabetic Patients: A Population-Based Retrospective Cohort Study in Taiwan

TLDR
The study showed that the long-term and regular use of fenofibrate may decrease the risk of incident retinopathy and the need for laser treatment in type 2 diabetic patients.

Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies

TLDR
Fenofibrate is effective in preventing progression of established diabetic Retinopathy in type 2 diabetes and should be considered for patients with pre-proliferative diabetic retinopathy and/or diabetic maculopathy, particularly in those with macular oedema requiring laser.

FIRST STUDY OF A LIPID-MODIFYING INTERVENTION TO SHOW SIGNIFICANT IMPACT ON DIABETIC EYE DISEASE PUBLISHED ON-LINE IN THE LANCET

TLDR
These data add to evidence of significant benefit with fenofibrate on other microvascular and macrovascular complications of diabetes in the FIELD study and are likely to impact on current guidelines for management of diabetes.
...

References

SHOWING 1-10 OF 55 REFERENCES

[Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].

TLDR
Treatment with the lipid lowering drug etofibrate seems to produce favourable therapeutic effects on hard exudates in diabetic background retinopathy in patients with diabetes mellitus and combined hyperlipoproteinemia.

Perspectives on diabetic retinopathy.

Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.

TLDR
Although progression to the primary outcome was not delayed, daily oral administration of RBX may delay progression of DME to a sight-threatening stage, and ruboxistaurin was well tolerated in this study.

Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy

TLDR
Atorvastatin may have a role in reducing diabetic retinal complications, with improvement in vascular resistance and decrease in the mean PSVs of the ophthalmic artery and CRA.

The effects of lipid lowering on diabetic retinopathy.

Laser Treatment in Diabetic Retinopathy

TLDR
When and how to perform laser treatment is described in detail, offering a proven treatment for many problems associated with diabetic retinopathy based on a high evidence level.

UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis

TLDR
Development of retinopathy (incidence) was strongly associated with baseline glycaemia, glycaemic exposure over 6 years, higher blood pressure and with not smoking and progression was associated with older age, male sex, hyperglycaemia (as evidenced by a higher HbA1 c) and withNot smoking.
...